PMID: 8469414Feb 19, 1993Paper

Diagnostic significance of skin immunolabelling with antibody against native cerebral amyloid in Alzheimer's disease

Neuroscience Letters
M IkedaS Hirai

Abstract

Skin taken from patients with Alzheimer's disease (AD) and control patient groups were immunolabelled using antisera against either purified native cerebral beta protein or synthetic beta peptide. Native amyloid antiserum frequently labelled vascular walls in AD skin but rarely in control skin. Semi-quantitative analysis of the positive vessels showed a significant difference between the two groups. Sweat glands and dermal nerves were labelled in both groups. However, synthetic beta peptide antiserum showed no significant difference. Vascular wall labelling in skin with native amyloid antiserum is useful in the differential diagnosis of AD.

Citations

Jun 9, 1995·Neuroscience Letters·J A VegaM T Fernández-Sánchez
Nov 5, 1997·Annals of the New York Academy of Sciences·R P FriedlandC A Marotta
Jun 1, 1996·The Tohoku Journal of Experimental Medicine·H Arai
Nov 14, 2006·Journal of the Neurological Sciences·Masaki IkedaKoichi Okamoto
Aug 2, 1996·The Journal of Biological Chemistry·D J Selkoe
Apr 23, 2019·Journal of Alzheimer's Disease : JAD·S Can AkermanGerhard Multhaup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Elizabeth GuihenWilliam T O'Connor
Proceedings of the National Academy of Sciences of the United States of America
Sumit PaliwalSamir Mitragotri
© 2021 Meta ULC. All rights reserved